Zai Lab Statement on Executive Management Team's Agreement on Share Activities
The Executive Officers of Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, today announced that they have each agreed that they do not anticipate selling any shares in Zai Lab through the remainder of 2024, except for any shares in existing Rule 10b5-1 plans that are currently effective or to cover tax obligations associated with the vesting of equity awards.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
Local and global experts are meeting in Nairobi, Kenya to update clinical practice guidelines as part of ongoing work with Allied Against Cancer?a collaboration between the National Comprehensive Cancer Network® (NCCN®), African...
Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today the U.S. Food and Drug Administration (FDA) has...
On April 30th, 2024, in celebration of Mental Health Awareness Month and AAPI Heritage Month, international award-winning classical pianist and pop-R&B singer Janet Noh released her newest record 'Oh Child' as well as its accompanying cinematic...
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the appointments of Ashley Nagle as Chief Business Officer (CBO) and Peter Finan, currently a Non-Executive Director, as Non-Executive...
With Denmark as the centre of gravity, the ambition is to invest in, support and advance some of the world's most promising quantum technology companies with applications in the life sciences.
The quantum industry, which develops novel technologies...
In a significant move to meet the growing demand for health management solutions, the 135th China Import and Export Fair ("Canton Fair" or "the Fair") has brought together top-tier companies from the Medicines, Health Products and Medical Devices...
